EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Delivery approaches of immunomodulatory nucleic acids for cancer therapy

Xiaomeng Hu, Tom Enbar, Li Tang

Current Opinion in Biotechnology · 2024

DOI: 10.1016/j.copbio.2024.103182 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Opinion in Biotechnology, 2024. Verfasst von Xiaomeng Hu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Bioengineering, École Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland. Hauptthemen laut MEDLINE: Neoplasms, RNA, Small Interfering. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: H2020 Marie Skłodowska-Curie Actions, Swiss Cancer League, Swiss National Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Messenger RNA (mRNA) vaccines have made remarkable public health contributions during the pandemic and initiated a new era for nucleic acid-based therapeutics. With the unique strength of nucleic acids, including not only mRNA but also DNA, microRNA, small interfering RNA (siRNA), and other nucleic acids, either in tuning off genes or introducing function, nucleic acid therapeutics have been regarded as potential candidates for the treatment of many different diseases, especially for the immunomodulation in cancer. However, the scope of the applications was limited by the challenges in delivery due to intrinsic properties of nucleic acids including low stability, immunogenicity, and toxicity. Bioengineering approaches toward efficient and targeted delivery of therapeutic nucleic acids have gained momentum in clinical applications in the past few decades. Recent advances in the biotechnological approaches for the delivery of mRNA, siRNA, and clustered regularly interspaced short palindromic repeats (CRISPR)/Cas for immunomodulatory are promising alternatives in designing future cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsRNA, Small InterferingHumansNucleic AcidsAnimalsImmunotherapyRNA, MessengerImmunomodulationCRISPR-Cas SystemsDrug Delivery SystemsImmunologic Factors

Substanzen

RNA, Small InterferingNucleic AcidsRNA, MessengerImmunologic Factors

Autor:innen und Institutionen

  • Institute of Bioengineering, École Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland.
  • Institute of Bioengineering, École Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland; Institute of Materials Science & Engineering, École Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausann…

Förderung

  • H2020 Marie Skłodowska-Curie Actions
  • Swiss Cancer League
  • Swiss National Science Foundation
  • Swiss Cancer Research Foundation
  • Horizon 2020
  • China Scholarship Council
  • Horizon 2020 Framework Programme
  • École Polytechnique Fédérale de Lausanne

Zitieren

APA

Hu, X., Enbar, T., & Tang, L. (2024). Delivery approaches of immunomodulatory nucleic acids for cancer therapy. Current Opinion in Biotechnology. https://doi.org/10.1016/j.copbio.2024.103182

Vancouver

Hu X, Enbar T, Tang L. Delivery approaches of immunomodulatory nucleic acids for cancer therapy. Current Opinion in Biotechnology. 2024. doi:10.1016/j.copbio.2024.103182

BibTeX
@article{Hu2024,
  author = {Hu, Xiaomeng and Enbar, Tom and Tang, Li},
  title = {Delivery approaches of immunomodulatory nucleic acids for cancer therapy},
  journal = {Current Opinion in Biotechnology},
  year = {2024},
  doi = {10.1016/j.copbio.2024.103182}
}
Kostenlos starten →